Xin Lang Cai Jing·2026-02-02 07:03Group 1 - The core point of the news is that Zhaoyan New Drug's stock price dropped by 5.05% to 36.09 CNY per share, with a trading volume of 569 million CNY and a turnover rate of 2.45%, resulting in a total market capitalization of 27.044 billion CNY [1] - Zhaoyan New Drug Research Center Co., Ltd. specializes in non-clinical safety evaluation services for drugs, with its main business revenue composition being 95.59% from non-clinical research services, 4.34% from clinical services, and 0.07% from experimental model supply [1] - The company was established on February 25, 1998, and was listed on August 25, 2017, located in Beijing Economic and Technological Development Zone [1] Group 2 - Among the top ten circulating shareholders of Zhaoyan New Drug, Huabao Fund's Huabao CSI Medical ETF (512170) reduced its holdings by 2.1693 million shares in the third quarter, now holding 12.4838 million shares, which accounts for 1.67% of the circulating shares [2] - The estimated floating loss for Huabao CSI Medical ETF today is approximately 23.9689 million CNY [2] - The fund was established on May 20, 2019, with a current scale of 25.263 billion CNY, and has achieved a year-to-date return of 4.77% and a one-year return of 14.49% [2]